Waters Corporation (NYSE: WAT) Reports Third Quarter 2024 Financial Results
Highlights
-
Sales of
$740 million exceeded guidance, grew 4% as reported and 4% in constant currency - Instruments returned to growth; recurring revenue grew high single-digits in constant currency
- All reported regions returned to growth in the quarter; sales grew across all end markets, led by Pharma & Industrial
-
GAAP EPS of
$2.71 and non-GAAP EPS of$2.93 significantly exceeded guidance, led by strong operational performance and better-than-expected market conditions - Raised full-year sales and EPS guidance, with 5% to 7% constant currency growth expected in the fourth quarter
Third Quarter 2024
Sales for the third quarter of 2024 were
On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2024 was
"We delivered exceptional third quarter results, fueled by new product adoption and improved customer spending trends," said Dr.
Other Highlights
During the third quarter of 2024, sales into the pharmaceutical market increased 2% as reported and 3% in constant currency. Sales into the industrial market increased 9% as reported and 7% in constant currency. Sales into the academic and government market increased 2% as reported and were flat in constant currency.
During the quarter, instrument system sales increased 1% as reported and in constant currency. Recurring revenues, which represent the combination of service and precision chemistries, increased 6% as reported and 7% in constant currency.
Geographically, sales in
Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company's website www.waters.com in the Investor Relations section.
Full-Year and Fourth Quarter 2024 Financial Guidance
Full-Year 2024 Financial Guidance
The Company is raising its full-year 2024 sales guidance, and now expects organic constant currency sales growth to be in the range of -0.9% to -0.3%. Currency translation is expected to decrease full-year sales growth by 1.2%. M&A contribution from the Wyatt transaction covering the first four-and-a-half months of the year has added 1.3% to full-year reported sales. The resulting full-year 2024 reported sales growth is expected in the range of -0.8% to -0.2%.
The Company is also raising its full-year 2024 non-GAAP EPS guidance to now be in the range of
Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full year.
Fourth Quarter 2024 Financial Guidance
The Company expects fourth quarter 2024 constant currency sales growth to be in the range of +5.0% to +7.0%. Currency translation is expected to decrease fourth quarter sales growth by 1.7%. The resulting fourth quarter 2024 reported sales growth is expected in the range of +3.3% to +5.3%.
The Company expects fourth quarter 2024 non-GAAP EPS to be in the range of
Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the fourth quarter.
Conference Call Details
About
Non-GAAP Financial Measures
This press release contains financial measures, such as organic constant currency growth rates, adjusted operating income, adjusted net income, adjusted earnings per diluted share and free cash flow, among others, which are considered "non-GAAP" financial measures under applicable
Cautionary Statement
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "feels", "believes", "anticipates", "plans", "expects", "intends", "suggests", "appears", "estimates", "projects" and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward- looking statements within this release for a variety of reasons, including and without limitation, risks related to, and expectations or ability to realize commercial success of the Wyatt transaction; the impact of this transaction on the Company's business, anticipated progress on Waters' research programs, development of new analytical instruments and associated software or consumables, manufacturing development and capabilities; the increased indebtedness of the Company as a result of the Wyatt transaction, the repayment of which could impact the Company's future results, market prospects for its products and sales and earnings guidance; foreign currency exchange rate fluctuations potentially affecting translation of the Company's future non-
|
|||||||
Consolidated Statements of Operations |
|||||||
(In thousands, except per share data) |
|||||||
(Unaudited) |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Three Months Ended |
|
Nine Months Ended |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
$ 740,305 |
|
$ 711,692 |
|
$ 2,085,673 |
|
$ 2,136,942 |
|
|
|
|
|
|
|
|
Costs and operating expenses: |
|
|
|
|
|
|
|
Cost of sales |
301,655 |
|
291,407 |
|
851,685 |
|
876,863 |
Selling and administrative expenses |
169,097 |
|
186,748 |
|
516,880 |
|
555,657 |
Research and development expenses |
45,336 |
|
41,995 |
|
136,113 |
|
130,559 |
Purchased intangibles amortization |
11,759 |
|
12,116 |
|
35,337 |
|
20,410 |
Litigation provision |
1,326 |
|
- |
|
11,568 |
|
- |
|
|
|
|
|
|
|
|
Operating income |
211,132 |
|
179,426 |
|
534,090 |
|
553,453 |
|
|
|
|
|
|
|
|
Other (expense) income, net |
(338) |
|
328 |
|
1,619 |
|
1,364 |
Interest expense, net |
(17,177) |
|
(26,559) |
|
(57,824) |
|
(56,174) |
|
|
|
|
|
|
|
|
Income from operations before income taxes |
193,617 |
|
153,195 |
|
477,885 |
|
498,643 |
|
|
|
|
|
|
|
|
Provision for income taxes |
32,114 |
|
18,643 |
|
71,449 |
|
72,614 |
|
|
|
|
|
|
|
|
Net income |
$ 161,503 |
|
$ 134,552 |
|
$ 406,436 |
|
$ 426,029 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per basic common share |
$ 2.72 |
|
$ 2.28 |
|
$ 6.85 |
|
$ 7.21 |
|
|
|
|
|
|
|
|
Weighted-average number of basic common shares |
59,367 |
|
59,093 |
|
59,314 |
|
59,061 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per diluted common share |
$ 2.71 |
|
$ 2.27 |
|
$ 6.83 |
|
$ 7.19 |
|
|
|
|
|
|
|
|
Weighted-average number of diluted common shares and equivalents |
59,504 |
|
59,255 |
|
59,471 |
|
59,262 |
|
|||||||||||||||
Reconciliation of GAAP to Adjusted Non-GAAP |
|||||||||||||||
|
|||||||||||||||
Three Months Ended |
|||||||||||||||
(In thousands) |
|||||||||||||||
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Constant |
|
|
|
|
|
Three Months Ended |
|
Percent |
|
Impact of |
|
Currency |
||||
|
|
|
|
|
|
|
|
|
Change |
|
Currency |
|
Growth Rate (a) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Waters |
|
|
$ |
655,652 |
|
$ |
629,348 |
|
4 % |
|
0 % |
|
4 % |
||
TA |
|
|
|
|
84,653 |
|
|
82,344 |
|
3 % |
|
1 % |
|
2 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
740,305 |
|
$ |
711,692 |
|
4 % |
|
0 % |
|
4 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Instruments |
|
|
$ |
323,076 |
|
$ |
319,431 |
|
1 % |
|
0 % |
|
1 % |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service |
|
|
|
278,294 |
|
|
263,611 |
|
6 % |
|
0 % |
|
6 % |
||
Chemistry |
|
|
|
138,935 |
|
|
128,650 |
|
8 % |
|
0 % |
|
8 % |
||
Total Recurring |
|
|
|
417,229 |
|
|
392,261 |
|
6 % |
|
(1 %) |
|
7 % |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
740,305 |
|
$ |
711,692 |
|
4 % |
|
0 % |
|
4 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
251,329 |
|
$ |
238,228 |
|
5 % |
|
(1 %) |
|
6 % |
|
|
|
|
|
279,136 |
|
|
275,479 |
|
1 % |
|
0 % |
|
1 % |
||
|
|
|
|
209,840 |
|
|
197,985 |
|
6 % |
|
2 % |
|
4 % |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
740,305 |
|
$ |
711,692 |
|
4 % |
|
0 % |
|
4 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
$ |
430,138 |
|
$ |
421,535 |
|
2 % |
|
(1 %) |
|
3 % |
||
Industrial |
|
|
|
227,740 |
|
|
209,449 |
|
9 % |
|
2 % |
|
7 % |
||
Academic & Government |
|
|
82,427 |
|
|
80,708 |
|
2 % |
|
2 % |
|
0 % |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
740,305 |
|
$ |
711,692 |
|
4 % |
|
0 % |
|
4 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of |
|
|
|||||||||||||||||
|
Reconciliation of GAAP to Adjusted Non-GAAP |
|||||||||||||||||
|
|
|||||||||||||||||
|
Nine Months Ended |
|||||||||||||||||
|
(In thousands) |
|||||||||||||||||
|
|
|||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Organic |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Constant |
|
|
|
|
|
|
Nine Months Ended |
|
Percent |
|
Impact of |
|
Impact of |
|
Currency |
||||
|
|
|
|
|
|
|
|
|
|
Change |
|
Currency |
|
Acquisitions |
|
Growth Rate (a) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Waters |
|
|
$ |
1,840,112 |
|
$ |
1,884,658 |
|
(2 %) |
|
(1 %) |
|
2 % |
|
(3 %) |
||
|
TA |
|
|
|
|
245,561 |
|
|
252,284 |
|
(3 %) |
|
(1 %) |
|
0 % |
|
(2 %) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
2,085,673 |
|
$ |
2,136,942 |
|
(2 %) |
|
(1 %) |
|
2 % |
|
(3 %) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Instruments |
|
|
$ |
859,079 |
|
$ |
964,380 |
|
(11 %) |
|
0 % |
|
3 % |
|
(14 %) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Service |
|
|
|
812,367 |
|
|
774,478 |
|
5 % |
|
(1 %) |
|
1 % |
|
5 % |
||
|
Chemistry |
|
|
|
414,227 |
|
|
398,084 |
|
4 % |
|
(1 %) |
|
0 % |
|
5 % |
||
|
Total Recurring |
|
|
|
1,226,594 |
|
|
1,172,562 |
|
5 % |
|
(1 %) |
|
1 % |
|
5 % |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
2,085,673 |
|
$ |
2,136,942 |
|
(2 %) |
|
(1 %) |
|
2 % |
|
(3 %) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
696,319 |
|
$ |
745,932 |
|
(7 %) |
|
(3 %) |
|
1 % |
|
(5 %) |
|
|
|
|
|
|
794,775 |
|
|
804,827 |
|
(1 %) |
|
0 % |
|
3 % |
|
(4 %) |
||
|
|
|
|
|
594,579 |
|
|
586,183 |
|
1 % |
|
2 % |
|
2 % |
|
(3 %) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
2,085,673 |
|
$ |
2,136,942 |
|
(2 %) |
|
(1 %) |
|
2 % |
|
(3 %) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
|
$ |
1,220,092 |
|
$ |
1,233,177 |
|
(1 %) |
|
(1 %) |
|
2 % |
|
(2 %) |
||
|
Industrial |
|
|
|
644,459 |
|
|
648,754 |
|
(1 %) |
|
0 % |
|
1 % |
|
(2 %) |
||
|
Academic & Government |
|
|
221,122 |
|
|
255,011 |
|
(13 %) |
|
1 % |
|
2 % |
|
(16 %) |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
$ |
2,085,673 |
|
$ |
2,136,942 |
|
(2 %) |
|
(1 %) |
|
2 % |
|
(3 %) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
The Company believes that referring to comparable organic constant currency growth rates is a useful way to evaluate the underlying performance of |
|
|||||||||||||||||||||||||||||
Reconciliation of GAAP to Adjusted Non-GAAP Financials |
|||||||||||||||||||||||||||||
Three and Nine Months Ended |
|||||||||||||||||||||||||||||
(In thousands, except per share data) |
|||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling & |
|
|
Research & |
|
|
|
|
|
Operating |
|
|
Other |
|
|
before |
|
|
Provision for |
|
|
|
|
|
Diluted |
|
|
|
|
|
Administrative |
|
|
Development |
|
|
Operating |
|
|
Income |
|
|
(Expense) |
|
|
Income |
|
|
Income |
|
|
Net |
|
|
Earnings |
|
|
|
|
|
Expenses (a) |
|
|
Expenses |
|
|
Income |
|
|
Percentage |
|
|
Income |
|
|
Taxes |
|
|
Taxes |
|
|
Income |
|
|
per Share |
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
GAAP |
|
|
$ |
182,182 |
|
$ |
45,336 |
|
$ |
211,132 |
|
|
28.5 % |
|
$ |
(338) |
|
$ |
193,617 |
|
$ |
32,114 |
|
$ |
161,503 |
|
$ |
2.71 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization (b) |
|
|
(11,759) |
|
|
- |
|
|
11,759 |
|
|
1.6 % |
|
|
- |
|
|
11,759 |
|
|
2,814 |
|
|
8,945 |
|
|
0.15 |
|
|
Litigation provision (c) |
|
|
(1,326) |
|
|
- |
|
|
1,326 |
|
|
0.2 % |
|
|
- |
|
|
1,326 |
|
|
318 |
|
|
1,008 |
|
|
0.02 |
|
|
Restructuring costs and certain other items (d) |
|
|
(1,194) |
|
|
- |
|
|
1,194 |
|
|
0.2 % |
|
|
- |
|
|
1,194 |
|
|
282 |
|
|
912 |
|
|
0.02 |
|
|
Retention bonus obligation (f) |
|
|
(1,909) |
|
|
(636) |
|
|
2,545 |
|
|
0.3 % |
|
|
- |
|
|
2,545 |
|
|
611 |
|
|
1,934 |
|
|
0.03 |
|
Adjusted Non-GAAP |
|
$ |
165,994 |
|
$ |
44,700 |
|
$ |
227,956 |
|
|
30.8 % |
|
$ |
(338) |
|
$ |
210,441 |
|
$ |
36,139 |
|
$ |
174,302 |
|
$ |
2.93 |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
GAAP |
|
|
$ |
198,864 |
|
$ |
41,995 |
|
$ |
179,426 |
|
|
25.2 % |
|
$ |
328 |
|
$ |
153,195 |
|
$ |
18,643 |
|
$ |
134,552 |
|
$ |
2.27 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization (b) |
|
|
(12,116) |
|
|
- |
|
|
12,116 |
|
|
1.7 % |
|
|
- |
|
|
12,116 |
|
|
2,901 |
|
|
9,215 |
|
|
0.16 |
|
|
Restructuring costs and certain other items (d) |
|
|
(24,057) |
|
|
- |
|
|
24,057 |
|
|
3.4 % |
|
|
(651) |
|
|
23,406 |
|
|
5,387 |
|
|
18,019 |
|
|
0.30 |
|
|
Acquisition related costs (e) |
|
|
(1,263) |
|
|
- |
|
|
1,263 |
|
|
0.2 % |
|
|
- |
|
|
1,263 |
|
|
303 |
|
|
960 |
|
|
0.02 |
|
|
Retention bonus obligation (f) |
|
|
(5,725) |
|
|
(1,909) |
|
|
7,634 |
|
|
1.1 % |
|
|
- |
|
|
7,634 |
|
|
1,832 |
|
|
5,802 |
|
|
0.10 |
|
Adjusted Non-GAAP |
|
$ |
155,703 |
|
$ |
40,086 |
|
$ |
224,496 |
|
|
31.5 % |
|
$ |
(323) |
|
$ |
197,614 |
|
$ |
29,066 |
|
$ |
168,548 |
|
$ |
2.84 |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
GAAP |
|
|
$ |
563,785 |
|
$ |
136,113 |
|
$ |
534,090 |
|
|
25.6 % |
|
$ |
1,619 |
|
$ |
477,885 |
|
$ |
71,449 |
|
$ |
406,436 |
|
$ |
6.83 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization (b) |
|
|
(35,337) |
|
|
- |
|
|
35,337 |
|
|
1.7 % |
|
|
- |
|
|
35,337 |
|
|
8,456 |
|
|
26,881 |
|
|
0.45 |
|
|
Litigation provision and settlement (c) |
|
|
(11,568) |
|
|
- |
|
|
11,568 |
|
|
0.6 % |
|
|
- |
|
|
11,568 |
|
|
2,776 |
|
|
8,792 |
|
|
0.15 |
|
|
Restructuring costs and certain other items (d) |
|
|
(10,680) |
|
|
- |
|
|
10,680 |
|
|
0.5 % |
|
|
- |
|
|
10,680 |
|
|
2,617 |
|
|
8,063 |
|
|
0.14 |
|
|
Retention bonus obligation (f) |
|
|
(11,451) |
|
|
(3,817) |
|
|
15,268 |
|
|
0.7 % |
|
|
- |
|
|
15,268 |
|
|
3,664 |
|
|
11,604 |
|
|
0.20 |
|
Adjusted Non-GAAP |
|
$ |
494,749 |
|
$ |
132,296 |
|
$ |
606,943 |
|
|
29.1 % |
|
$ |
1,619 |
|
$ |
550,738 |
|
$ |
88,962 |
|
$ |
461,776 |
|
$ |
7.76 |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
GAAP |
|
|
$ |
576,067 |
|
$ |
130,559 |
|
$ |
553,453 |
|
|
25.9 % |
|
$ |
1,364 |
|
$ |
498,643 |
|
$ |
72,614 |
|
$ |
426,029 |
|
$ |
7.19 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization (b) |
|
|
(20,410) |
|
|
- |
|
|
20,410 |
|
|
1.0 % |
|
|
- |
|
|
20,410 |
|
|
4,852 |
|
|
15,558 |
|
|
0.26 |
|
|
Restructuring costs and certain other items (d) |
|
|
(28,881) |
|
|
- |
|
|
28,881 |
|
|
1.4 % |
|
|
(651) |
|
|
28,230 |
|
|
6,860 |
|
|
21,370 |
|
|
0.36 |
|
|
Acquisition related costs (e) |
|
|
(13,298) |
|
|
- |
|
|
13,298 |
|
|
0.6 % |
|
|
- |
|
|
13,298 |
|
|
3,191 |
|
|
10,107 |
|
|
0.17 |
|
|
Retention bonus obligation (f) |
|
|
(8,368) |
|
|
(2,790) |
|
|
11,158 |
|
|
0.5 % |
|
|
- |
|
|
11,158 |
|
|
2,678 |
|
|
8,480 |
|
|
0.14 |
|
Adjusted Non-GAAP |
|
$ |
505,110 |
|
$ |
127,769 |
|
$ |
627,200 |
|
|
29.4 % |
|
$ |
713 |
|
$ |
571,739 |
|
$ |
90,195 |
|
$ |
481,544 |
|
$ |
8.13 |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
________________________________ |
||||||||||||||||||||||||||||||
(a) |
Selling & administrative expenses include purchased intangibles amortization and litigation provisions and settlements. |
|||||||||||||||||||||||||||||
(b) |
The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time. |
|||||||||||||||||||||||||||||
(c) |
Litigation provisions and settlement gains were excluded as these items are isolated, unpredictable and not expected to recur regularly. |
|||||||||||||||||||||||||||||
(d) |
Restructuring costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company. |
|||||||||||||||||||||||||||||
(e) |
Acquisition related costs include all incremental expenses incurred, such as advisory, legal, accounting, tax, valuation, and other professional fees. The Company believes that these costs are not normal and do not represent future ongoing business expenses. |
|||||||||||||||||||||||||||||
(f) |
In connection with the Wyatt acquisition, the Company started to recognize a two-year retention bonus obligation that is contingent upon the employee's providing future service and continued employment with Waters. The Company believes that these costs are not normal and do not represent future ongoing business expenses. |
|
|||||||
Preliminary Condensed Unclassified Consolidated Balance Sheets |
|||||||
(In thousands and unaudited) |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents and investments |
|
$ 331,458 |
|
$ 395,974 |
|||
Accounts receivable |
|
|
|
669,534 |
|
702,168 |
|
Inventories |
|
|
|
518,994 |
|
516,236 |
|
Property, plant and equipment, net |
|
642,627 |
|
639,073 |
|||
Intangible assets, net |
|
|
591,883 |
|
629,187 |
||
|
|
|
|
|
1,306,593 |
|
1,305,446 |
Other assets |
|
|
|
450,531 |
|
438,770 |
|
Total assets |
|
|
|
$ 4,511,620 |
|
$ 4,626,854 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes payable and debt |
|
|
$ 1,826,248 |
|
$ 2,355,513 |
||
Other liabilities |
|
|
|
1,082,273 |
|
1,121,000 |
|
Total liabilities |
|
|
|
2,908,521 |
|
3,476,513 |
|
|
|
|
|
|
|
|
|
Total stockholders' equity |
|
|
1,603,099 |
|
1,150,341 |
||
Total liabilities and stockholders' equity |
|
$ 4,511,620 |
|
$ 4,626,854 |
|
|||||||||||
Preliminary Condensed Consolidated Statements of Cash Flows |
|||||||||||
Three and Nine Months Ended |
|||||||||||
(In thousands and unaudited) |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|||
|
Net income |
$ 161,503 |
|
$ 134,552 |
|
|
$ 406,436 |
|
$ 426,029 |
||
|
Adjustments to reconcile net income to net |
|
|
|
|
|
|
|
|
||
|
|
|
cash provided by operating activities: |
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
10,647 |
|
8,490 |
|
|
32,993 |
|
32,224 |
|
|
|
Depreciation and amortization |
47,507 |
|
47,807 |
|
|
143,250 |
|
117,845 |
|
|
|
Change in operating assets and liabilities and other, net |
(15,077) |
|
(33,031) |
|
|
(60,695) |
|
(203,411) |
|
|
|
|
Net cash provided by operating activities |
204,580 |
|
157,818 |
|
|
521,984 |
|
372,687 |
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
|||
|
Additions to property, plant, equipment |
|
|
|
|
|
|
|
|
||
|
|
|
and software capitalization |
(25,618) |
|
(38,047) |
|
|
(90,377) |
|
(119,044) |
|
Business acquisitions, net of cash acquired |
- |
|
- |
|
|
- |
|
(1,285,907) |
||
|
(Investments in) proceeds from unaffiliated companies |
(425) |
|
651 |
|
|
(1,489) |
|
651 |
||
|
Net change in investments |
(8) |
|
(5) |
|
|
(44) |
|
(21) |
||
|
|
|
Net cash used in investing activities |
(26,051) |
|
(37,401) |
|
|
(91,910) |
|
(1,404,321) |
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|||
|
Net change in debt |
(180,000) |
|
(125,181) |
|
|
(530,000) |
|
929,601 |
||
|
Proceeds from stock plans |
3,237 |
|
9,464 |
|
|
25,073 |
|
18,092 |
||
|
Purchases of treasury shares |
(141) |
|
(692) |
|
|
(13,475) |
|
(70,433) |
||
|
Other cash flow from financing activities, net |
20 |
|
2,884 |
|
|
15,305 |
|
8,178 |
||
|
|
|
Net cash used in financing activities |
(176,884) |
|
(113,525) |
|
|
(503,097) |
|
885,438 |
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents |
2,442 |
|
(171) |
|
|
8,461 |
|
2,081 |
|||
|
|
|
Increase (decrease) in cash and cash equivalents |
4,087 |
|
6,721 |
|
|
(64,562) |
|
(144,115) |
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of period |
326,427 |
|
329,693 |
|
|
395,076 |
|
480,529 |
|||
|
|
|
Cash and cash equivalents at end of period |
$ 330,514 |
|
$ 336,414 |
|
|
$ 330,514 |
|
$ 336,414 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of GAAP Cash Flows from Operating Activities to Free Cash Flow (a) |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities - GAAP |
$ 204,580 |
|
$ 157,818 |
|
|
$ 521,984 |
|
$ 372,687 |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments: |
|
|
|
|
|
|
|
|
||
|
|
Additions to property, plant, equipment |
|
|
|
|
|
|
|
|
|
|
|
|
and software capitalization |
(25,618) |
|
(38,047) |
|
|
(90,377) |
|
(119,044) |
|
|
Tax reform payments |
- |
|
- |
|
|
95,645 |
|
72,101 |
|
|
|
Litigation settlements (received) paid, net |
- |
|
(375) |
|
|
9,250 |
|
(1,125) |
|
|
|
Major facility renovations |
- |
|
3,291 |
|
|
- |
|
12,151 |
|
|
|
Payment of acquired Wyatt liabilities (b) |
- |
|
- |
|
|
- |
|
25,617 |
|
|
|
Payment of Wyatt retention bonus obligation (c) |
- |
|
- |
|
|
19,770 |
|
- |
|
Free Cash Flow - Adjusted Non-GAAP |
$ 178,962 |
|
$ 122,687 |
|
|
$ 556,272 |
|
$ 362,387 |
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
The Company defines free cash flow as net cash flow from operations accounted for under GAAP less capital expenditures and software capitalizations plus or minus any unusual and non recurring items. Free cash flow is not a GAAP measurement and may not be comparable to free cash flow reported by other companies. |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
(b) |
In connection with the Wyatt acquisition, the Company assumed certain obligations of Wyatt and paid those obligations immediately upon closing the transaction. The Company believes that the assumed obligations do not represent future ongoing business expenses. |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
(c) |
During the nine months ended |
|
|||||||||
Reconciliation of Projected GAAP to Adjusted Non-GAAP Financial Outlook |
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Twelve Months Ended |
|
Three Months Ended |
||||
|
|
|
|
|
|
||||
|
|
|
|
Range |
|
|
|
Range |
|
Projected Sales |
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
Organic constant currency sales growth rate (a) |
(0.9 %) |
- |
(0.3 %) |
|
5.0 % |
- |
7.0 % |
||
Impact of: |
|
|
|
|
|
|
|
|
|
|
Currency translation |
(1.2 %) |
- |
(1.2 %) |
|
(1.7 %) |
- |
(1.7 %) |
|
|
Acquisitions |
1.3 % |
- |
1.3 % |
|
‒ |
- |
‒ |
|
Sales growth rate as reported |
(0.8 %) |
- |
(0.2 %) |
|
3.3 % |
- |
5.3 % |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Range |
|
|
|
Range |
|
Projected Earnings Per Diluted Share |
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
GAAP earnings per diluted share |
$ 10.55 |
- |
$ 10.75 |
|
$ 3.72 |
- |
$ 3.92 |
||
Adjustments: |
|
|
|
|
|
|
|
|
|
|
Purchased intangibles amortization |
$ 0.60 |
- |
$ 0.60 |
|
$ 0.15 |
- |
$ 0.15 |
|
|
Litigation settlement |
$ 0.15 |
- |
$ 0.15 |
|
$ - |
- |
$ - |
|
|
Restructuring costs and certain other items |
$ 0.14 |
- |
$ 0.14 |
|
$ - |
- |
$ - |
|
|
Retention bonus obligation |
$ 0.23 |
- |
$ 0.23 |
|
$ 0.03 |
- |
$ 0.03 |
|
Adjusted non-GAAP earnings per diluted share |
$ 11.67 |
- |
$ 11.87 |
|
$ 3.90 |
- |
$ 4.10 |
|
|
|
|
|
|
|
|
|
|
(a) Organic constant currency growth rates are a non-GAAP financial measure that measures the change in net sales between current and prior year periods, excluding the impact of foreign currency exchange rates during the current period and excluding the impact of acquisitions made within twelve months of the acquisition close date. These amounts are estimated at the current foreign currency exchange rates and based on the forecasted geographical sales in local currency, as well as an assessment of market conditions as of today, and may differ significantly from actual results. |
|||||||||
|
|
|
|
|
|
|
|
|
|
These forward-looking adjustment estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance. |
Contact:
View original content:https://www.prnewswire.com/news-releases/waters-corporation-nyse-wat-reports-third-quarter-2024-financial-results-302293299.html
SOURCE